Pneumococcal Conjugate Vaccine not checked

Sanofi · PCV21 vaccine · PCV21

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
7 active
11 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular”In the company’s words, NCT06736041 on ClinicalTrials.gov
Tested for
Pneumococcal Immunization (5 trials), Pneumococcal Infections, Sickle Cell Disease
Main trialPhase 3
“The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).”In the company’s words, NCT06838000 on ClinicalTrials.gov
Other names
PCV21 vaccine · Pneumococcal Conjugated Vaccine · PCV21 · 515 · SP0202-IIb · SP0202-VI · SP0202-VII

Other drugs for Pneumococcal Immunization

All 15 drugs for Pneumococcal Immunization

Coming up7

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Dec 2026 Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Phase 3Recruiting 7 Jan 2027 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Phase 3Active, not recruiting 17 May 2027 Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Phase 3Recruiting 7 Jun 2027 Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
Phase 3Active, not recruiting 25 Aug 2027 Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Phase 3Active, not recruiting 10 Sep 2027 Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Phase 3Active, not recruiting 22 Oct 2027 Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Phase 3Completed Sep 2013 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Phase 2Completed 9 Aug 2021 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Phase 2Completed 10 Aug 2023 Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Phase 1Completed 30 Sep 2019 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pneumococcal Conjugate Vaccine

Following is part of Solo: you see every change to Pneumococcal Conjugate Vaccine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in